Omnicell Com Stock Price, News & Analysis

Omnicell (NASDAQ:OMCL) reported strong Q2 2025 financial results, exceeding previous guidance. Total revenues reached $291 million, up 5% year-over-year, with GAAP net income of $6 million ($0.12 per share) and non-GAAP net income of $21 million ($0.45 per share).

The company maintains a solid balance sheet with $399 million in cash and equivalents, while operating cash flow was $43 million. Notable achievements include the launch of MedVision and MedTrack/MedTrack-OR solutions, HITRUST CSF i1 certification for OmniSphere, and the opening of a new Innovation Lab in Austin.

Based on strong H1 2025 performance, Omnicell raised its full-year 2025 guidance, projecting total revenues of $1.13-1.16 billion and non-GAAP EPS of $1.40-1.65.

Omnicell (Nasdaq:OMCL), a pharmacy and nursing care delivery model transformation company, has scheduled its Q2 2025 financial results release for July 31, 2025, before market open.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Participants can join via phone using the numbers (800) 715-9871 (U.S.) or (646) 307-1963 (international) with Conference ID 3131192. The webcast will be accessible through Omnicell's Investor Relations website.

Omnicell (NASDAQ:OMCL) has announced an improved profit outlook for Q2 and full-year 2025, driven by reduced China import tariffs from 145% to 30%. The company updated its Q2 2025 Non-GAAP EBITDA guidance to $25-31 million (up from $22-30 million) and Non-GAAP EPS to $0.24-0.34 (up from $0.19-0.32). For full-year 2025, Omnicell maintains its revenue guidance of $1.105-1.155 billion while raising the lower end of its Non-GAAP EBITDA guidance to $120-145 million (from $100-145 million). Additionally, the company announced a new $75 million stock repurchase program, supplementing its existing 2016 program with $2.7 million remaining. Each 25% reduction in tariffs below 145% after August 12, 2025, is expected to reduce tariff impact on profitability by approximately $2 million in 2025.

Omnicell (NASDAQ: OMCL) has unveiled new products aimed at enhancing medication management in perioperative and clinic settings. The company introduced two key innovations: MedTrack RFID Line and MedVision. The MedTrack RFID system features MedTrack-OR, an RFID-enabled drawer designed for operating rooms that automatically tracks non-controlled medications with a 'grab-and-go' workflow. MedVision is a web-enabled software solution for outpatient clinics that provides real-time inventory management, automatic reordering capabilities, and optional Epic MAR integration. Additionally, Omnicell announced the opening of its new Innovation Lab in Austin, Texas, focused on developing solutions for medication and supply management challenges. These innovations aim to address healthcare staffing shortages while improving inventory accuracy and operational efficiency.

Omnicell (NASDAQ:OMCL) has announced the opening of its new Innovation Lab in Austin, Texas. The facility, located at 1005 East St. Elmo Road, will focus on developing automated technologies to address challenges in medication and supply management within healthcare settings. The lab will employ an "innovation sprint" model to rapidly develop and test solutions for customer-identified problems, ranging from simple mechanical designs to advanced robotics, AI, autonomous devices, sensor technologies, and machine vision.

The initiative aims to help hospitals and health systems combat rising costs and staffing shortages through innovative automation solutions. The lab's team of engineers and product managers will work on streamlining healthcare operations and reducing manual tasks, enabling healthcare workers to focus on patient care.

Omnicell (NASDAQ:OMCL) reported Q1 2025 financial results exceeding previous guidance. Total revenues reached $270 million, up 10% year-over-year, driven by growth in XT Amplify program and SaaS services. The company posted a GAAP net loss of $7 million ($0.15 per share), improving from a $16 million loss in Q1 2024. Non-GAAP net income was $12 million ($0.26 per share). The company maintains a strong balance sheet with $387 million in cash and equivalents. However, due to potential tariff impacts, Omnicell updated its full-year 2025 guidance, now expecting total revenues of $1.105-1.155 billion and non-GAAP earnings per share of $1.00-1.65. The company is expanding its presence with new facilities in Austin and Bangalore to enhance product development and cloud strategy.

Omnicell (Nasdaq: OMCL), a leader in pharmacy and nursing care delivery model transformation, has scheduled the release of its first quarter 2025 financial results before market open on Tuesday, May 6, 2025.

The company will host a conference call and webcast to discuss the results at 8:30 a.m. ET on the same day. Interested parties can join via phone using the numbers (800) 715-9871 (U.S.) or (646) 307-1963 (international) with Conference ID 7437144. The presentation will also be accessible through a live and archived webcast on Omnicell's Investor Relations website.

Omnicell (NASDAQ: OMCL) has appointed Perry A. Genova, PhD as Senior Vice President and Chief Technology Officer, effective March 31, 2025. Dr. Genova brings over 25 years of experience in product development, strategic planning, and regulatory compliance across medical device, pharmaceutical, and life sciences industries.

In his new role, Dr. Genova will spearhead Omnicell's technology strategy, focusing on addressing medication and supply management challenges across care settings to advance the company's vision of the Autonomous Pharmacy. According to Executive Vice President and COO Nnamdi Njoku, Genova's entrepreneurial mindset is expected to play a important role in advancing Omnicell's multi-year, outcome-centric growth strategy.

Omnicell (NASDAQ:OMCL) announced that Executive Vice President and Chief Financial Officer Nchacha Etta will step down from his position, effective September 15, 2025, or until a successor is named. The company has initiated a national search for his replacement.

Etta, who joined Omnicell in mid-2023, will continue in his role during the transition period. Chairman, President, CEO, and founder Randall Lipps acknowledged Etta's contributions in integrating recent acquisitions and implementing operational efficiencies during challenging industry conditions.

The company has also reiterated its first quarter and full year 2025 guidance, previously announced in their Q4 2024 earnings release on February 6, 2025. Omnicell maintains its focus on executing strategic priorities and driving long-term revenue growth while supporting customers in achieving enhanced clinical and operational outcomes.